Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial


Creative Commons License

KAZANCI F., YÜKSEL D., EZGÜ F. S., ERDEM O., ONAN M. A.

Journal of Clinical Obstetrics & Gynecology, cilt.33, sa.2, ss.81-87, 2023 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 2
  • Basım Tarihi: 2023
  • Doi Numarası: 10.5336/jcog.2022-94609
  • Dergi Adı: Journal of Clinical Obstetrics & Gynecology
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, Central & Eastern European Academic Source (CEEAS), EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.81-87
  • Gazi Üniversitesi Adresli: Evet

Özet

Objective: The dysregulation of metabolism is a hallmark of cancer. Enzymes of tricarboxylic acid (TCA) cycle have a key role in pathogenesis of carcinogenesis as oncometabolits. The variants in fumarate hydratase (FH) gene have been linked to sporadic tumors and familial tumor propensity. To asses the prevalence of variants in the FH gene in endometrial carcinoma (EC) and uterine leiomyo mas (UL). Material and Methods: This prospective study included 58 patients with EC and 44 with UL. The FH gene variants were analyzed in the DNA samples collected from peripheral circulation. All exons of the FH gene were replicated by polymerase chain reaction utilizingspecific primers including intron-exon boundaries and than was sequenced with Sanger method.Results: Only two variants were detected in two different pa- tients. The c.927G>A (p.Pro309Pro) and c.63C>T (p.Ala21Ala) variants were observed in patients with UL, EC respectively. c.927G >A (p.Pro309=) and c.63C>T (p.Ala21=) are rare variants inside the overall population with allele frequency ranges of 0.02428, 0.0 00014 re- spectively. Conclusion: The contribution of variants in genes encoding the TCA cycle enzymes in tumor cells has provided understanding fundamental role on metabolic alterations in carcinogenesis. Further studies are needed to discover the novel tumor mutations and identify ap- propriate treatment.